A phase 3 trial (NEJ026) conducted in untreated NSCLC patients with EGFR mutations who were randomly assigned to receive either erlotinib plus bevacizumab combination therapy or erlotinib monotherapy showed that bevacizumab plus EGFR-TKI as a first-line treatment for patients with advanced non-squamous EGFR-mutant NSCLC significantly prolonged progression-free survival (PFS) [15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.